Direct lineage tracing reveals Activin-a potential for improved pancreatic homing of bone marrow mesenchymal stem cells and efficient β-cell regeneration in vivo

Nidheesh Dadheech 1,2, Abhay Srivastava 1, Mitul Vakani 1, Paresh Shrimali 1, Ramesh Bhonde 3 and Sarita Gupta 1*

Abstract

Background: Despite the potential, bone marrow-derived mesenchymal stem cells (BMSCs) show limitations for beta (β)-cell replacement therapy due to inefficient methods to deliver BMSCs into pancreatic lineage. In this study, we report TGF-β family member protein, Activin-a potential to stimulate efficient pancreatic migration, enhanced homing and accelerated β-cell differentiation.

Methods: Lineage tracing of permanent green fluorescent protein (GFP)-tagged donor murine BMSCs transplanted either alone or in combination with Activin-a in diabetic mice displayed potential β-cell regeneration and reversed diabetes.

Results: Pancreatic histology of Activin-a treated recipient mice reflected high GFP+BMSC infiltration into damaged pancreas with normalized fasting blood glucose and elevated serum insulin. Whole pancreas FACS profiling of GFP+ cells displayed significant homing of GFP+BMSC with Activin-a treatment (6%) compared to BMSCs alone transplanted controls (0.5%). Within islets, approximately 5% GFP+ cells attain β-cell signature (GFP+ Ins+) with Activin-a treatment versus controls. Further, double immunostaining for mesenchymal stem cell markers CD44+/GFP+ in infiltrated GFP+BMSC deciphers substantial endocrine reprogramming and β-cell differentiation (6.4% Ins+/GFP+) within 15 days.

Conclusion: Our investigation thus presents a novel pharmacological approach for stimulating direct migration and homing of therapeutic BMSCs that re-validates BMSC potential for autologous stem cell transplantation therapy in diabetes.

Keywords: Bone marrow mesenchymal stem cells, Activin-a, Lineage tracing, β-cell differentiation

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Stem cell-derived β-cells present a clear proof-of-concept for cell-based diabetes medication. After “Novacell protocol,” substantial progress has been made in generating stem cell-derived β-cells from embryonic stem (ES) cells, induced pluripotent stem (iPS) cells, or adult progenitor cells [1–3]. BMSCs, however, show great promise for diabetes mitigation both in rodents and newly diagnosed individuals with type-1 diabetes [4–7]. Previous studies have shown that rodent BMSCs spontaneously differentiate into endocrine pancreatic cells [8–10]. The mechanism, however, remains largely unknown to state whether BMSCs can transdifferentiate into β-cells in vivo or are required to support paracrine interplay for existing β-cell growth and differentiation?

Most studies addressing the contribution of BMSCs in β-cell survival or regeneration have used transplantation of naïve BMSC, while some others have used genetic tag, i.e., GFP for monitoring transplanted cells [11, 12]. An early study by Hess et al. demonstrated the blood glucose-lowering effect within a week after intravenous infusion of GFP-tagged allogenic BMSCs into STZ-induced diabetic mice [4]. The authors reported as low as 0.5% frequency of donor GFP+BMSC to reach the pancreas while fewer differentiate into insulin-producing cells within the host islets. In another similar study, only 1% allogenic chimerism of repopulated BMSCs were shown to reach recipient pancreas and reverse diabetes in NOD mice [12]. Ianus et al. also showed that infused BMSCs can differentiate into insulin-producing islet cells when transplanted into lethally irradiated mice [8]. Interestingly, few other groups replicating similar studies with BMSCs reported no evidence for such an anti-diabetic effect after BMSC infusion [11, 13, 14].

The migration of BMSCs to colonize in degenerating pancreas appears to be the key for stimulating β-cell regeneration [15, 16]. Moreover, a method to stimulate pancreatic migration and trans-differentiation into β-cells limits their scope in cell therapy. It has been extensively demonstrated that the CXCR4stromal-derived factor-1 axis is crucial for BMSC migration and homing. Modulating the expression of the CXCR4 gene in BMSC could alleviate their tissue-specific homing [17, 18]. The use of chemical/biological modulators such as TGF-β family member protein Activin-a is shown to support differentiation of BMSCs [3, 19, 20]. Furthermore, Activin-a induces definitive endoderm differentiation by stimulating CXCR4 expression in ES/iPS cell-derived β-cells and regulate migration to enhance homing [21–23].

We, therefore, used a lineage tracing approach in STZ-induced diabetic mice to demonstrate the potential of Activin-a in stimulating migration, improving pancreatic homing and efficient endogenous β-cell differentiation.

Material and methods

Animals
Animal protocols were approved and performed as per Committee for the Purpose of Control and Supervision on Experiments on Animals (CPCSEA) and our Institutional Animal Ethics Committee (IAEC, MSU Baroda) (License no: 938/PO/a/06/CPCSEA) guidelines. We used male Balb/c mice, 6–8 weeks old, weighing 25–30 g and housed at 26 °C with 12 h light-dark cycle and food/water ad libitum.

Diabetes induction and blood glucose measurement
Diabetes was induced by 5 days multiple low dose streptozotocin (STZ) injections (70 mg/kg b wt). Fasting blood glucose was monitored with Accu-Chek Glucometer.

Isolation and purification bone marrow-derived mesenchymal stem cells
BMSCs were isolated from the tibia and femur bones of 4-week-old balb/c mice by modifying the protocols adapted from Zhu et al. and Hsiao et al. using differential trypsinization steps [24, 25]. For a more detailed protocol, please refer to supplementary methods.

Generation of permanently labeled GFP+BMSC
One hundred thousand donor BMSCs were transfected with pPB-eGFP (1 μg) and pCYL43-PBase (2 μg) DNA vector (a gift from Sanger Institute, UK; for map, see supplementary figure-1) using lipofectamine 2000 (Invitrogen) in 1:3 volume ratio. Following transfection, stable GFP-expressing clones were selected on puromycin antibiotic at 300 μg/ml for the first 2 days and 900 μg/ml for the next 7 days. GFP+ BMSCs colonies were hand-picked using 3.2 mm clonal discs (Sigma Aldrich, USA) and FACS sorted for enriched GFP+ cells (see supplementary methods for cloning and purification strategy).

Flow cytometry
Live BMSCs at p#25 or single islet cells were acquired on BD Aria-III flow cytometer for GFP+ cell quantification. For immunocharacterization, formalin-fixed BMSCs or islet cells were stained for MSC surface markers (CD34, CD44, CD90, CD45, CD117, Vimentin, and SMA) and endocrine differentiation antibodies (CD49b and PDX1). Cells were fixed in 4% formalin (30 min on ice), Triton-X100 permeabilized, and stained with primary labeled antibodies overnight at 4 °C for key MSCs and endocrine differentiation markers (see Table 1 for details). Data were acquired on BD Aria-III sorter using DIVA software and later analyzed with FlowJo software (FlowJo, USA).

In vitro differentiation of BMSC into islet-like clusters
GFP+BMSCs were assessed for in vitro islet differentiation and formation of ILCC using Activin-a (20 ng/ml) as described previously [26, 27].
Transplantation of GFP-labeled BMSCs
For lineage tracing, one million GFP + BMSCs were pre-incubated with Activin-a (2.5 μg/ml) for 30 min prior to the transplants and then injected intravenously into STZ-induced diabetic recipient mice, followed by daily Activin-a injections (25 μg/kg b wt) for 15 days post-transplantation. Diabetic STZ treated mice (control) did not receive donor GFP-labeled BMSC and Activin-a treatment, while a group of recipient mice received only donor GFP + BMSC without Activin-a treatment, served as BMSC control.

Tissue preparation and immunohistochemistry
Pancreatic tissues from all mice at day 30 post diabetes induction were harvested, formalin-fixed, and sliced in 5 μm sections while BMSC for immunocytochemistry were fixed in 10% formalin overnight. For histology, tissue sections were deparaffinized with grading xylene and ethanol grades and rehydrated in water. Both tissues or cells were permeabilized and blocked with 4% donkey serum (Sigma Aldrich, USA) for 1 h at RT, followed by primary antibodies (see Table 1 for details) incubation overnight at 4°C. The next day, cells were washed and labeled with secondary antibodies (see Table 2 for details) for 30 min at RT. Nuclei were marked with DAPI and mounted with Fluoromount-G (VECTASHIELD, USA). Images were captured on LSM710 confocal microscope and analyzed using Zen10 software (Carl Zeiss, USA).

Protein extraction and Western blotting
FACS-sorted green cells and single-cell islet suspension from diabetic and recipient mice isolated islets were lysed in RIPA buffer (1% triton X-100, 1% sodium deoxycholate, 0.1% SDS, 0.15 mM NaCl, 0.01 M Sodium Phosphate, pH 7.2). Fifteen micrometers protein after bradford quantification was loaded on 12% SDS-page to transfer onto a nitrocellulose membrane. Membranes

### Table 1 List of primary antibodies

| Sr. no. | Antibody | Company and catalog no. | Isotype IgG | Mono/polyclonal Ab | Mol. weight (KDa) | Application | Dilution |
|---------|----------|-------------------------|------------|-------------------|------------------|-------------|----------|
| 1       | Nestin   | Sigma#N5413             | Rabbit     | Poly              | 177              | Western     | 1:1000   |
| 2       | Pdx-1    | BD#554655               | Mouse      | Mono              | 40               | Western/IF  | 1:1000/1:200 |
| 3       | Neurogenin-3 | Sigma #SAB1300585       | Rabbit     | Poly              | 23               | Western/IF  | 1:1000   |
| 4       | β-Actin  | BD#612657               | Mouse      | Mono              | 42               | Western     | 1:10000  |
| 5       | Nestin-PE| BD#561230               | Mouse      | Mono              | 177              | IF          | 1:100    |
| 6       | Insulin  | CST#4590                | Rabbit     | Poly              | 6                | IF          | 1:100    |
| 7       | Glucagon | Sigma#G2654             | Mouse      | Mono              | 3.48             | IF          | 1:100    |
| 8       | Somatostatin | Sigma #SAB4502861       | Mouse      | Poly              | 12               | IF          | 1:100    |
| 9       | CD90.2-FITC | BD#55302              | Rat        | Mono              | ~20              | Flowcytometry/IF | 1:10/1:500 |
| 10      | CD44-PE  | BD#553134               | Rat        | Mono              | 82               | Flowcytometry/IF | 1:10/1:500 |
| 11      | CD34-FITC | BD#553733              | Rat        | Mono              |                      | Flowcytometry      | 1:10      |
| 12      | CD45-APC | BD#559864               | Rat        | Mono              |                      | Flow cytometry      | 1:10      |
| 13      | CD117-PE | BD#553869               | Rat        | Mono              |                      | Flowcytometry      | 1:10      |
| 14      | CD49b    | BD#554999               | Rat        | Mono              |                      | Flowcytometry      | 1:10      |
| 15      | Vimentin | Sigma#C9080             | Mouse      | Mono              | 53               | IF          | 1:400    |
| 16      | Smooth muscle actin | Sigma#F3777 | Mouse      | Mono              | 42               | IF          | 1:250    |
| 17      | C-Peptide | CST#4593               | Rabbit     | Mono              | 5                | IF          | 1:100    |

### Table 2 List of secondary antibodies

| Sr. no. | Antibody           | Company and catalog no. | Isotype IgG | Mono/polyclonal Ab | Application | Dilution |
|---------|--------------------|-------------------------|------------|-------------------|-------------|----------|
| 1       | Anti-Mouse-IgG-HRP | Jackson ImmunoResearch #115-035-003 | Goat | Poly | Western | 1:5000 |
| 2       | Anti-Rabbit-IgG-HRP | Jackson Immuno Research #111-035-003 | Goat | Poly | Western | 1:5000 |
| 3       | Anti-Mouse-IgG-FITC | Sigma#F8771             | Goat       | Poly              | IF          | 1:200   |
| 4       | Anti-Rabbit-IgG-FITC | Sigma#F9887              | Goat       | Poly              | IF          | 1:200   |
| 5       | Anti-Mouse-IgG-CF555 | Sigma#SAB4600299        | Goat       | Poly              | IF          | 1:100   |
| 6       | Anti-Rabbit-IgG-CF555 | Sigma#SAB4600068       | Goat       | Poly              | IF          | 1:100   |
were blocked with 1% BSA in PBS and probed with primary antibodies (see Table 1) at 4 °C overnight. The HRP-labeled secondary antibody was then probed for 30 min at RT. Membranes were finally stained with Chemiluminescence detection reagent and images were captured on the gel documentation system (GE Healthcare). Densitometric protein expression was measured from pooled cell extracts from 3 mice in duplicates, and fold changes with SD were calculated using Fiji software.

Serum insulin ELISA
Serum insulin from animals was measured using a mouse insulin ELISA kit (Mercodia Inc., USA).

Statistical analysis
All statistical analysis was performed using GraphPad Prism-6 software using either two-way ANOVA or Bonferroni test for p value calculations with > 95% confidence. Statistics is described in legends for each figure. The number of mice transplanted is limited to N = 3 due to the huge cost incurred for daily Activin-a injections.

Results
Derivation, generation and characterization of GFP⁺BMSC
We isolated BMSCs from donor mice surgically by modifying the previously described protocols from Zhu et al. and Hsiao et al. [24, 25]. A homogeneous population of BMSC without hematopoietic and macrophage contamination was achieved by differential trypsinization technique [25]. To perform lineage tracing of BMSCs, we created traceable BMSCs by permanent genomic integration of GFP using piggyback transposomal elements (Fig. 1a; Suppl. Fig-1). BMSCs by permanent genomic integration of GFP using piggyback transposomal elements (Fig. 1a; Suppl. Fig-1). Transfected BMSCs show a high frequency of GFP⁺ cells with flowcytometry (90.6%). Fluorescent imaging also confirmed the presence of high GFP signals in the FACS-sorted clone (Fig. 1b, Suppl. Fig-2). We further confirmed mesenchymal markers profiling post-genetic modification and observed GFP⁺ BMSC retained the characteristics. Transfected cells displayed positive expression for CD44 (97.6%) (Fig. 1c), CD34 (88.9%), CD90 (87.5%), CD117 (18.5%), Nestin (48.9%), Vimentin (99.5%), Smooth muscle actin (89%), and pancreatic duodenal homeobox-1 (8.67%) (Suppl. fig-3), while negative expression for CD45 (1.67%) (Fig. 1c) and CD49b (0.17%) (Suppl. fig-3). These marker expressions correspond to BMSC according to the International Society of Cellular Therapy System [28]. It has been well known that human BMSCs do not express the CD34 marker, but at least in mice, there are marked differences in the CD34 expression profile. These have been discussed widely in two independent reports confirming the presence of CD34 expression in murine BMSCs [29, 30].

In vitro β-cell generation potential of GFP⁺BMSC
Prior to lineage tracing experiments, we examined the β-cell differentiation potential of genetically labeled BMSCs using Activin-a growth factor, ex vivo, as previously reported [26, 31]. Genome integrated GFP⁺BMSC showed effective cell clustering at day 2 deciphered into islet-like aggregates by day 4 till day 7, similar to the non-transfected control BMSC (Suppl. fig-1b). After 7 days of differentiation, islet-like clusters were stained for dithizone staining and confirmed for the presence of vimentin expression (red) and insulin (green) (Fig. 1d).

Model of pancreatic injury and lineage tracing of GFP⁺BMSC to contribute to the new β-cell formation
To evaluate the BMSC potential for repair and restoring lost β-cell mass, we adopted the STZ-induced diabetic model for partial β-cell ablation and mild hyperglycemia. As per National Institutes of Health (NIH) and the Animal Models of Diabetic Complications Consortium (AMDC C), USA, the recommended blood glucose level for diabetes induction in STZ-treated mice under a non-fasting state should be > 200 mg/dl (11.1 mmol/l), whereas for a fasted animal, it should be > 150 mg/dl (8.4 mM) [32, 33]. Hence, we injected STZ at 70 mg/kg body weight for 5 days to attain glycemia > 11 mM in a fasted condition. It has been well documented that the pancreatic transcriptional reprogramming markers are only expressed at early time points for a very short duration during the β-cell regeneration process. To study BMSC-derived β-cell regeneration, it is mandated to perform lineage tracing studies early-on, post-transplantation. Hence, we performed lineage tracing on day 30.

We designed an experimental approach to study pancreatic repair upon transplantation of donor allogeneic GFP-expressing BMSC (Fig. 2a). Fasting blood glucose more than 15 mM for 30 days and depleted serum insulin levels confirm the model establishment for β-cell death (Fig. 2c, d) Histo-morphological assessment of pancreatic sections stained with hematoxylin and eosin (H + E) and immunohistochemistry for insulin (red) showed pancreatic injury and β-cell damage in islets at day 30, resulting in hypoinsulinemia and hyperglycemia (Fig. 2f, g). Another set of diabetic un-transplanted representative mice (n = 2) was sacrificed and the pancreas was harvested solely to survey the GFP expression in pancreatic cells by flow cytometry and microscopy and found negative for GFP signals (Fig. 2e). Established hyperglycemic recipient mice were intravenously transplanted with transgenic GFP⁺BMSC, and blood glucose...
and serum insulin levels were measured. Control non-diabetic mice retained physiological glycemic control over the total duration of the study, while non-transplanted diabetic mice exhibited a hyperglycemic response after STZ injection with elevated blood glucose and severely depleted insulin levels (Fig. 2f, g). The data from mice transplanted with allogenic GFP*BMSC without Activin-a treatment followed a similar glycemic pattern as the diabetic controls and fails to reverse diabetes. These findings coincide with the earlier similar reports where BMSC failed to reverse hyperglycemia. Additionally, in another group of our experimental design, where
mice transplanted with GFP⁺BMSC and also treated with Activin-a for 15 days, interestingly, we found a profound effect of this treatment on glucose-lowering and increased serum insulin levels after 30 days. We speculate that these results reflecting the reversal of diabetes in Activin-a treatment mice could be attributed to two possibilities: (1) GFP⁺BMSC contributes to a new β-cell generation that resulted in increased insulin and
reduced blood glucose, and (2) Activin-a treatment substantially stimulate insulin biosynthesis or release from pre-existing β-cells. To further test this, we performed lineage tracing and surveyed GFP-expressing cells in recipient mice’s pancreas and liver. The aim is to survey for the evidence of transgenic BMSC contributing to β-cell regeneration.

**Activin-a treatment stimulates pancreatic migration and homing of GFP+BMSC**

We hypothesized that the effect on blood glucose and serum insulin levels in Activin-a treatment mice with bone marrow-derived stem cells is a result of the new β-cell formation. To investigate this, we first examined the migration pattern and homing of GFP-expressing BMSC in diabetic control and GFP+BMSC transplanted mice under the influence of Activin-a treatment. Pancreas and liver tissues harvested at day 30 from all groups of animals were digested to single-cell suspension for FACS quantification of GFP+ cells. Whole pancreatic cells sorting from diabetic control and BMSC transplanted mice without Activin-a treatment displayed less than 1% (0.7 ± 0.44) GFP+ cell migrating to the pancreas, whereas BMSC recipient mice treated with Activin-a presented significantly higher GFP 6 ± 0.42% expressing cells (Fig. 3a). Subsequently, no significant migration and homing were observed into the liver in all the groups (Fig. 3b), suggesting that Activin-a could only promote efficient pancreatic lineage migration of GFP+ BMSC but not into the liver.

Further, to identify the specific molecular signature of pancreas migrated GFP+ cells, we performed FACS profiling for GFP+ cells with CD44 (mesenchymal marker) in the single-cell population. Both normal (0.12 ± 0.01%) and diabetic control (0.13 ± 0.01%) mice islet cells did not present CD44+ cells, indicating that MSCs do not considerably reside within the islets. However, untreated diabetic recipient mice displayed approximately 0.31 ± 0.21%, while Activin-a treated recipient showed a significantly high number of CD44+ cells (2.12 ± 0.31%), respectively, within the total cell population (Fig. 3d, Suppl. Fig-4). The fact that recipient mice received allogeneic BMSC, we then quantified the presence of GFP+ cells specifically within the islet cell population. As expected, controls and untreated recipient diabetic mice pancreata contained an extremely low number of GFP+ cells out of total islet population (control 0.75 ± 0.001%, diabetic control 0.83 ± 0.091%, and GFP-BMSC transplanted 0.51 ± 0.21%). Activin-a treated transplanted mice dramatically displayed a high frequency of GFP+ cells (4.72 ± 0.87%) within the isolated islet cell population (Fig. 3e). This implied that Activin-a treatment in recipient mice could potentially stimulate efficient migration and improved homing of transplanted BMSCs to the injured pancreas.

If the donor BMSC were to contribute to new islet cell generation with Activin-a, we hypothesize that the subset of migratory GFP+ cells in islets should demonstrate loss of CD44 expression without losing GFP signals. The GFP+CD44− cells thereby present evidence of donor BMSC cell trans-differentiation into new islet cells. To do this, we FACS analyzed the dual stained (GFP/CD44) islet cells in each group. Again, no dual-stained cells in both controls were detected. A tiny fraction of undifferentiated GFP+CD44− cells (0.13 ± 0.01%) was observed in untreated donor BMSC recipient mice. Similarly, Activin-a treated recipients demonstrated 3.67 ± 0.13% GFP+CD44− (differentiated) and only 0.57 ± 0.07% GFP+CD44− (undifferentiated) cells (Fig. 3c, e). The extent of differentiation of donor BMSC could be calculated by subtracting the frequency of undifferentiated cells GFP+CD44− from the total GFP+ cells quantified within the islets. We observed 25% of cells (0.13 out of 0.51%) of donor GFP+BMSC in untreated and 88% cells (4.15% out of 4.72%) of donor GFP+BMSC in Activin-a treated BMSC transplanted animals undergo trans-differentiation (Fig. 3f, Suppl. Fig-5). These observations collectively indicate that despite the potential, due to the fairly low migration of transplanted donor BMSC into the injured pancreas, not enough BMSCs could deliver and transdifferentiate into new insulin-producing cells which ultimately accounts for donor BMSC failure to mitigate hyperglycemia in control BMSC alone, recipients. On the other side, Activin-a treatment in conjunction with BMSC infusion in the recipient mice demonstrated this proof-of-concept for BMSC transdifferentiation.

Although BMSC in untreated animals holds the similar potential to produce new islet cells, however, due to the fairly low migration of transplanted donor BMSC into damaged islets, not enough BMSC deliver new insulin-producing cells and ultimately fails donor BMSC to reverse hyperglycemia in non-treated animals, unlike Activin-a treated ones.

**Transplanted GFP+ donor BMSC gives rise to β-cells in injured pancreas revealing evidence of β-cells neogenesis with Activin-a treatment**

To investigate the endogenous β-cell regeneration, we compared the total number of insulin+ cells and GFP-expressing insulin cells in the pancreas. In our experimental model for lineage tracing using GFP+BMSC as shown in Fig. 4a, at day 30, GFP+Ins+ cells would denote endogenous β-cell regeneration while the dual-positive GFP+Ins+ cells would confirm trans-differentiation of transplanted bone marrow-derived cells. Immunohistochemistry in diabetic control mice did not display any GFP-expressing cells but reduced insulin immunopositive region depicted β-cells damaged by STZ treatment (Fig. 4b). Further, occasional scattered GFP+ cells were
observed in the acinar region of untreated BMSC transplanted mice but devoid of insulin co-expression reflected the presence of undifferentiated BMSCs within islets. Moreover, in Activin-a-treated recipient mice, we could find a high ratio of GFP+ cells in acinar, ducts, and islet regions. These animals presented 8.7 ± 0.46% GFP+ cells, of which 6.4 ± 0.30% were GFP+ β-cells per section of pancreatic tissue (Fig. 4c). We recorded the GFP-expressing cells infiltrated in large-sized islets co-expressing insulin as well as small clusters or β-cell...
**Fig. 4** In vivo lineage tracing of transplanted GFP+ BMSC in recipient mice pancreas. **a** Schematic representation of the experimental model to lineage trace GFP+ BMSC contributing to new β-cell generation. **b** Representative image from Activin-a treated GFP + BMSC recipient mouse pancreas showing GFP-labeled β-cells by co-immunostained for GFP (green) with insulin (red). Nuclei were stained with Dapi (blue). The graph displays quantification of **c** total GFP+ cells and **d** GFP+ β-cells within the islets of regenerating the pancreas. Data represent mean ± SEM with $N$ = 3 mice per group. All statistical analyses were performed using Graphpad Prism software using two-way ANOVA and Bonferroni test for $p$ value calculations. **e** Representative confocal microscopic images of immunostaining for insulin (red) and GFP (green) representing infiltration of transplanted GFP+ BMSC in mature islets and ductal regions. Small clusters of GFP+ β-cell present evidence for de novo BMSC-derived β-cell formation from the transplanted BMSC. Nuclei were stained with Dapi (blue). **f** Proteomic characterization by western blotting and densitometric quantification of key pancreatic endocrine differentiation transcription factors from FACS sorted islet cells of 3 pooled representative mouse pancreas, depicting evidence of new β-cell differentiation markers. Chemiluminescence signals were exposed for 1–2 min and images were captured on the Gel Documentation system (GE Healthcare) and analyzed with ImageJ software. A single cropped area of key proteins from each condition is represented, while the graph represents densitometry quantification for each protein with standard deviation from 3 pooled mice cell extracts in duplicates.
aggregates (Fig. 4d, Suppl. Fig-6). Interestingly, the entire cells in these clusters were found to be GFP positive along with insulin co-immunostaining, representing an index of β-cell neogenesis.

**Activin-a-mediated Neurogenin-3 re-activation suggests the mechanism of trans-differentiation into GFP+BMSC-derived β-cells**

Using FACS-sorted single GFP+β-cells from BMSC controls and Activin-a treated BMSC recipient mice pancreas, we investigated the mechanism of new β-cell formation by protein expression. Western blot analysis for key mesenchymal stem cells (CD90 and CD44) and β-cell differentiation markers (Nestin, Pdx1, and Neurog3) suggested neuroendocrine reprogramming in GFP+ cells with Activin-a treatment. FACS-sorted green cells demonstrate high expression of CD90 in Activin-a-treated animals compared to STZ-treated diabetic controls. Correspondingly, CD44 remains fairly undetectable in diabetic control and Activin-a-treated groups Vs untreated BMSC recipients, suggesting lineage transformation of GFP+BMSC into endocrine cells with Activin-a treatment. Increased protein expression of nestin, pdx1, and neurog3 in Activin-a treated BMSC recipients provides clear evidence for pancreatic endocrine cell reprogramming with sequential activation of β-cell transcription factors. Neurog3 re-activation in GFP+BMSC deciphers mechanism of trans-differentiation into new β-cells (Fig. 4e, Suppl. Fig-7).

**Discussion**

Over two decades, several studies presented shreds of evidence for generating β-cells from BMSC [34, 35]. Despite the BMSC potential, the underlying mechanism that governs critical signals for migration and homing of BMSC remains elusive. Lack of evidence and efficacy in migration for β-cell regeneration remained questionable.

Hess et al. reported a lowering of blood glucose levels and 0.5–2% GFP+ cells reaching the pancreas [4]. Subsequently, others have reported no significant trans-differentiation of BMSC into insulin-producing cells, in vivo [14]. Our recent study suggests that permanently GFP-expressing BMSCs can efficiently reverse chemical-induced hyperinsulinemia and hyperglycemia. Using an endocrine cell-differentiating agent, Activin-a, we were now able to force prominent migration and colonization of GFP+BMSCs into the injured pancreas. We believe that pre-incubation of BMSCs with Activin-a and enhanced CXCR4 expression in infused BMSCs could potentially accelerate the pancreatic migration and triggers endocrine differentiation for β-cell trans-differentiation. Our results redefined significant migration of GFP+BMSC (~ 6%) into diabetic pancreas with Activin-a treatment, compared to 0.5–1% homing in BMSC transplanted/diabetic controls.

Wang et al. in 2006 reported that transplantation of GFP+BMSCs into neonatal mice displayed 40% cell migration into exocrine while only a few contributes to the endocrine compartment [36]. We further redefine this with Activin-a that improves the absolute homing of BMSC specifically into endocrine (islets) fraction. Flow analysis of GFP and CD44 dual markers (Fig. 3e) and insulin/GFP imaging (Fig. 4b, d) confirm this observation. Other reports raised the concern of BMSC contributing to the development of fibrosis [37–39]; however, we did not observe this. We anticipate this could be potentially an outcome of crude bone marrow population infusion (including hematopoietic cells) while we have used more enriched and characterized and BMSC populations.

The presence of GFP+ β-cells within islets and small β-cell clusters in Activin-a treated mice confers endogenous pancreatic regeneration by BMSC transdifferentiation with daily Activin-a injections. We believe this is attributed to key endocrine transcriptional reprogramming initiation with Activin-a treatment. Protein expression profiling from FACS sorted green cells display concrete evidence for new β-cell generation and reveal a new mechanism of transdifferentiation by sequential activation of β-cell differentiation markers, precisely via neurogenin-3 re-activation in migrated GFP+BMSCs.

Our method of endogenous pancreatic regeneration using BMSCs and differentiation growth factors like Activin-a could substantially influence a newer paradigm of cell therapy for diabetes in a wider diabetic population using GMP grade autologous BMSCs transplantation.

**Conclusion**

Our study concludes Activin-a potentiation in migration, homing, and β-cell differentiation of transplanted BMSCs. This novel pharmacological approach for stimulating direct migration and homing of therapeutic BMSCs reignites the scope for autologous BMSC trans-plantation therapy to treat diabetes.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s13287-020-01843-z.

**Additional file 1: Supplementary Figure 1.** (a) Vector map depicting pPBGFp and pCyL43 Pbase plasmids for genomic-integrating and constitutively expressing GFP in transfected BMSC. (b) Islet differentiation stages and immunostaining representative images. **Supplementary Figure 2.** (a) Pictorial representation of BMSC clone selection strategy using flowcytometry, (b) FACS profiling, gating and sorting parameter images for positive GFP-BMSC clone, (c) Gating strategy and analysis used for population selection with doublet discrimination before BMSC surface immunophenotyping FACS quantification, and (d) representative FACS graphs for confirming cell viability and death using propidium iodide staining and fluorescent image of GFP (green) co-labelled with dapi nuclear staining. **Supplementary Figure 3.** Comparative immunophenotyping characterization of unmodified and genetically modified BMSCs with key mesenchymal, hematopoietic and pancreatic endocrine cell markers with...
flow-cytometry. Supplementary Figure 4. Comprehensive flow cytometric quantification of percentage (a) total CD44+ population and (b) GFP population and within the injured pancreas in controls non-recipients and treated BMSC recipients with and without Activin-a treatment. Supplementary Figure 5. Comprehensive flow cytometric quantification of percentage GFP+CD44+ expressing dual population in FACs sorted single islet cell suspension. Supplementary Figure 6. (a) Immunocytochemical images from islet-like structures differentiated from GFP+BMSC. (b) pancreatic immunohistochemical sections from GFP+BMSC and GFP+BMSC + Activin-a treated animals. Supplementary Figure 7. Unedited western blot images for mesenchymal stem cells and pancreatic differentiation transcription factors.

Additional file 2: Supplementary Methods.

Abbreviations
BMSC: Bone marrow-derived mesenchymal stem cells; GFP: Green fluorescent protein; ESC: Embryonic stem cells; iPSC: Induced pluripotent stem cells; STZ: Streptozotocin; FACS: Flowcytometry

Acknowledgements
We also thank Dr. MM Panicker, NCBS, India, and Wellcome trust sanger institute, UK, for proving us the piggyBac plasmids for creating GFP-labeled BMSC.

Authors’ contributions
Conceived and designed the experiments: ND, SG. Performed the experiments: ND, AS, MV, PS. Analyzed the data: ND, RRB, SG. Contributed reagents/materials/analysis tools: ND, RRB, SG. Wrote the paper: ND, SG. SG is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The authors read and approved the final manuscript.

Funding
This work was supported by the Department of Biotechnology, Government of India, New Delhi, India, for funding the project (grant no. BT/PR9564/BRB/10/975/2011) and DBT-MSUB-ILSPARE programme (Grant no. BT/PR14551/INF/22/122/2010) for establishing a high-end central instrumental facility for microscopy and flow cytometry at Maharaja Sayajirao University, Baroda, India.

Availability of data and materials
All relevant data are within the paper and its Supporting Information files.

Ethics approval and consent to participate
This research finding has been approved by the ethics committee of The M S University of Baroda, Baroda, India.

Consent for publication
Not applicable.

Competing interests
The authors declare no conflict of interest for this study.

Author details
1Molecular Endocrinology and Stem Cell Research Laboratory, Department of Biochemistry, Faculty of Science, The M.S. University of Baroda, Vadodara, Gujarat, India. 2Department of Surgery, Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada. 3Dr. D. Y. Patil Vidyapeeth, Pimpri, Pune, Maharashtra, India.

Received: 7 January 2020 Revised: 7 June 2020 Accepted: 20 July 2020 Published online: 30 July 2020

References
1. Ramya VK, Marast M, Arsoms KE, Schatz DA, Peck AB, Cornelius JS. Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. Nat Med. 2006;12(3):278–82.
2. Phadnis SM, Joglekar MV, Dalvi MP, Muthyala S, Nair PD, Ghaskadbi SM, et al. Human bone marrow-derived mesenchymal cells differentiate and mature into endothelial pancreatic lineage in vivo. Cytotherapy. 2011;13(3):279–93.
3. D’Amour KA, Bang AG, Elizer S, Kelly OG, Agulnick AD, Smart NG, et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. 2006;24(11):1392–401.
4. Hess D, Li L, Martin M, Sakano S, Hill D, Strutt B, et al. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat Biotechnol. 2003;21(7):763–70.
5. Xie QP, Huang H, Xu B, Dong X, Gao SL, Zhang B, et al. Human bone marrow mesenchymal stem cells differentiate into insulin-producing cells upon microenvironmental manipulation in vitro. Differentiation. 2009;77(5):483–91.
6. Sordi V, Piemonti L. The contribution of hematopoietic stem cells to beta-cell replacement. Curr Diab Rep. 2009;9(2):119–24.
7. Banerjee M, Bhonde RR. Autologous bone marrow transplantion/ mobilization: a potential regenerative medicine for systemic degenerative disorders and healthy living. Med Hypotheses. 2007;68(6):1247–51. https://doi.org/10.1016/j.mehy.2006.09.069.
8. Ianus A, Holz GG, Theise ND, Hussain MA. In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J Clin Invest. 2003;111(6):845–50.
9. Zhao M, Amiel SA, Ajami S, Jiang J, Rela M, Heaton N, et al. Amelioration of streptozotocin-induced diabetes in mice with cells derived from human marrow stromal cells. PLoS One. 2008;3(7):e2666.
10. Luo L, Luo JZ, Xiong F, Abidi M, Greer D. Cytokines inducing bone marrow SCA+ cells migration into pancreatic islet and conversion into insulin-positive cells in vivo. PLoS One. 2009;4(2):e4504.
11. Choi JI, Uchino H, Azuma K, Ishii K, Ishizuka Y, Mochizuki H, et al. Little evidence of transdifferentiation of bone marrow-derived cells into pancreatic beta cells. Diabetologia. 2003;46(10):1366–74.
12. Zorina TD, Subbotin VM, Bertera S, Alexander AM, Halszczak C, Gambrell B, et al. Recovery of the endogenous beta cell function in the NOD model of autoimmune diabetes. Stem Cells. 2003;21(4):377–88.
13. Bellhack GF, Schefold JC, Weisssman IL, Taylor C, Jerabek L, Burge MJ, et al. Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. Diabetes. 2003;52(1):59–68.
14. Lechner A, Yang YG, Blacken RA, Wang L, Nolam AB, Hamben JP. No evidence for significant transdifferentiation of bone marrow into pancreatic beta-cells in vivo. Diabetes. 2004;53(3):616–23.
15. Ohtake K, Saito T, Satch Y, Kenjo A, Kimura T, Asawa S, et al. Bone marrow traffic to regenerating islets induced by streptozotocin injection and partial pancreatectomy in mice. Transplant Proc. 2008;40(2):449–51.
16. Tессен JS, Jensen JN, Pelli H, Dai XM, Zong XH, Stanley ER, et al. Critical roles for macrophages in islet angiogenesis and maintenance during pancreatic degeneration. Diabetes. 2008;57(6):1605–17.
17. De Becker A, Ret W. Homing and migration of mesenchymal stromal cells: how to improve the efficacy of cell therapy? World J Stem Cells. 2016;8(3):73–87. https://doi.org/10.4556/wjst.v8.i3.73.
18. Katoh M, Katoh M. Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors. Int J Oncol. 2010;36(2):415–20.
19. Hill CS. TGF-beta signalling pathways in early Xenopus development. Curr Opin Genet Dev. 2001;11(5):533–40.
20. Florio P, Lusio S, Marchetti P, Lupi R, Cobellis L, Falaschi C, et al. Activin A stimulates insulin secretion in cultured human pancreatic islets. J Endocrinol Invest. 2000;23(4):231–4.
21. Zong W, Lai Y, Yu T, Xia ZS, Yuan YH, Ouany H, et al. Wnt and Nodal signaling simultaneously induces definitive endoderm differentiation of mouse embryonic stem cells. Romanian J Morphol Embryol. 2017;58(2):51–7.
22. Zhang W, Li W, Chen T, Yang J, Wen Z, Yan X, et al. Activin A can induce definitive endoderm differentiation from human parthenogenetic embryonic stem cells. Biotechnol Lett. 2015;37(8):1711–7. https://doi.org/10.1007/s10529-015-1829-x.
23. Yasunaga M, Tada S, Torikai-Nishikawa S, Nakano Y, Okada M, Jakt LM, et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. 2006;24(11):1392–401.
24. Zhu H, Guo ZX, Jiang XX, Li H, Wang XY, Ye HY, et al. A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone. Nat Protoc. 2010;5(3):550–60.
25. Hsiao FS, Cheng CC, Peng SY, Huang HY, Lian WS, Jan ML, et al. Isolation of therapeutically functional mouse bone marrow mesenchymal stem cells
within 3 h by an effective single-step plastic-adherent method. Cell Prolif. 2010;43(3):235–48.

26. Dadheech N, Srivastava A, Paranjape N, Gupta S, Dave A, Shah GM, et al. Swertisin an anti-diabetic compound facilitate islet neogenesis from pancreatic stem/progenitor cells via p-38 MAP kinase-SMAD pathway: an in-vitro and in-vivo study. PLoS One. 2015;10(6):e0128244.

27. Dadheech N, Srivastava A, Belani M, Gupta S, Pal R, Bhonde RR, et al. Basal expression of pluripotency-associated genes can contribute to stemness property and differentiation potential. Stem Cells Dev. 2013;22(1):1802–17.

28. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7. e-pub ahead of print 2006/08/23. https://doi.org/10.1080/14653240600855905.

29. Lin CS, Ning H, Lin G, Lue TF. Is CD34 truly a negative marker for mesenchymal stromal cells? Cytotherapy. 2012;14(10):1159–63. e-pub ahead of print 2012/10/17. https://doi.org/10.3109/14653249.2012.729817.

30. Sharma A, Rani R. Do we really need to differentiate mesenchymal stem cells into insulin-producing cells for attenuation of the autoimmune responses in type 1 diabetes: immunoprophylactic effects of precursors to insulin-producing cells. Stem Cell Res Ther. 2017;8(1):167. e-pub ahead of print 2017/07/14. https://doi.org/10.1186/s13287-017-0615-1.

31. Dadheech N, Soni S, Srivastava A, Dadheech S, Gupta S, Gopurappilly R, et al. A small molecule Swertisin from Enicostemma littorale differentiates NIH3T3 cells into islet-like clusters and restores normoglycemia upon transplantation in diabetic Balb/c mice. Evid Based Complement Alternat Med. 2013;2013:280392.

32. Furman BL. Streptozotocin-induced diabetic models in mice and rats. Curr Protoc Pharmacol. 2015;70(5):47 41–20. https://doi.org/10.1002/0471141755.ph0547s70.

33. Breyer MD, Bottinger E, Brosius FC 3rd, Coffman TM, Harris RC, Heilig CW, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2005;16(1):27–45. https://doi.org/10.1681/ASN.2004080648.

34. Gao F, Wu DQ, Hu YH, Jin GX, Li GD, Sun TW, et al. In vitro cultivation of islet-like cell clusters from human umbilical cord blood-derived mesenchymal stem cells. Transl Res. 2008;151(6):302–302.

35. Chao KC, Chao RF, Fu YS, Liu SH. Islet-like clusters derived from mesenchymal stem cells in Wharton’s jelly of the human umbilical cord for transplantation to control type 1 diabetes. PLoS One. 2008;3(1):e1451.

36. Wang G, Bun nell BA, Painter RG, Quiniones BC, Tom S, Larson NA Jr, et al. Adult stem cells from bone marrow stroma differentiate into airway epithelial cells: potential therapy for cystic fibrosis. Proc Natl Acad Sci U S A. 2005;102(1):186–91.

37. Watanabe T, Masamune A, Kikuta K, Hirota M, Kume K, Satoz H, et al. Bone marrow contributes to the population of pancreatic stellate cells in mice. Am J Physiol Gastrointest Liver Physiol. 2009;297(6):G1138–46.

38. Sparmann G, Kruse ML, Hofmeister-Melke N, Kocz an D, Jaster R, Liebe S, et al. Bone marrow-derived pancreatic stellate cells in rats. Cell Res. 2010; 20(3):288–98.

39. Russo FP, Alison MR, Bigger BW, Amofah E, Florou A, Amin F, et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology. 2006;130(6):1807–21.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.